Stacey Titus • March 4, 2024
Vanderbilt Heart and Vascular Institute– Nashville, TN

Vanderbilt Heart and Vascular Institute is among the best heart programs in the nation and the top-ranked program in Tennessee. The Genetic Cardiomyopathy Program and the multidisciplinary care team deliver expert care for HCM in adults and children and provide genetic counseling for their families. The Vanderbilt Team has additional board certifications in advanced heart disease, advanced imaging, cardiopulmonary exercise testing, arrhythmias, congenital heart disease, structural catheter-based intervention, and cardiac surgery. The Vanderbilt Team works closely with the doctors at Monroe Carell Jr. Children’s Hospital at Vanderbilt to help transition families from pediatric care to adult care. The team creates a care plan that meets your unique health goals and needs. Vanderbilt Health is one of the top heart transplant programs in the world, providing patients with outstanding outcomes and access to innovative new research and treatments.

The HCMA held a BigHearted Warriors Unite Webinar Series on Tuesday, March 5th, 2024 with the team at Vanderbilt Heart and Vascular Institute. In case you missed it here is the link to view the recording on Youtube HERE

.

For more information on the Vanderbilt Heart and Vascular Institue HCM Program in Nashville, TN, please visit:  HERE


For more information on all HCMA Recognized Centers of Excellence, please visit HERE

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts